Statins: Multiple neuroprotective mechanisms in neurodegenerative diseases

Experimental Neurology

Volumn 230, Issue 1, 2011, Pages 27-34

  Wang, Qing ^a,b   Yan, Junqiang ^a   Chen, Xiaohong ^a   Li, Jin ^a   Yang, Yu ^a   Weng, JianPing ^a   Deng, Chao ^b   Yenari, Midori A ^c  

^a THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b UNIVERSITY OF WOLLONGONG   (Australia)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Inflammation; Ischemia; Neuroprotection; Parkinson's disease; Statins

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; ATORVASTATIN; CHOLESTEROL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MATRIX METALLOPROTEINASE; NITRIC OXIDE; PRAVASTATIN; REACTIVE OXYGEN METABOLITE; ROSUVASTATIN; SIMVASTATIN;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; BRAIN BLOOD FLOW; BRAIN ISCHEMIA; BRAIN REGION; COGNITIVE DEFECT; DISEASE COURSE; DRUG EFFECT; DRUG MECHANISM; HUMAN; LIPOPROTEIN BLOOD LEVEL; MULTIINFARCT DEMENTIA; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CHOLESTEROL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; NITRIC OXIDE SYNTHASE TYPE III; SIGNAL TRANSDUCTION;

EID: 79958027663     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2010.04.006     Document Type: Review

References (116)

1. Aelst L.W., D'Souza-Schorey C. Rho GTPases and signaling networks. Genes Dev. 1997, 11:2295-2322.
2. Aloisi F. Immune function of microglia. Glia 2001, 36(2):165-179.
3. Amarenco P., Goldstein L.B., Messig M., O'Neill B.J., Callahan A., Sillesen H., Hennerici M.G., Zivin J.A., Welch K.M. Relative and cumulative effects of lipid and blood pressure control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial. Stroke 2009, 40(7):2486-2492. SPARCL Investigators.
4. Aoki T., Kataoka H., Ishibashi R., Nozaki K., Hashimoto N. Simvastatin suppresses the progression of experimentally induced cerebral aneurysms in rats. Stroke 2008, 39(4):1276-1285.
5. Asahi M., Huang Z., Thomas S., Yoshimura S., Sumii T., Mori T., Qiu J., Amin-Hanjani S., Huang P.L., Liao J.K., Lo E.H., Moskowitz M.A. Protective effects of statins involving both eNOS and tPA in focal cerebral ischemia. J. Cereb. Blood Flow Metab. 2005, 25(6):722-729.
6. Assini A., Cammarata S., Vitali A., Colucci M., Giliberto L., Borghi R., Inglese M.L., Volpe S., Ratto S., Dagna-Bricarelli F., Baldo C., Argusti A., Odetti P., Piccini A., Tabaton M. Plasma levels of amyloid beta-protein 42 are increased in women with mild cognitive impairment. Neurology 2004, 63(5):828-831.
7. Bar-On P., Crews L., Koob A.O., Mizuno H., Adame A., Spencer B., Masliah E. Statins reduce neuronal alpha-synuclein aggregation in in vitro models of Parkinson's disease. J. Neurochem. 2008, 105(5):1656-1667.
8. Becker C., Jick S.S., Meier C.R. Use of statins and the risk of Parkinson's disease: a retrospective case-control study in the UK. Drug Saf. 2008, 31(5):399-407.
9. Berger C., Xia F., Maurer M.H., Schwab S. Neuroprotection by pravastatin in acute ischemic stroke in rats. Brain Res. Rev. 2008, 58(1):48-56.
10. Bonarek M., Barberger-Gateau P., Letenneur L., Deschamps V., Iron A., Dubroca B., Dartigues J.F. Relationships between cholesterol, apolipoprotein E polymorphism and dementia: a cross-sectional analysis from the PAQUID study. Neuroepidemiology 2000, 19:141-148.
11. Boshuizen H.C., Izaks G.J., van Buuren S., Ligthart G.J. Blood pressure and mortality in elderly people aged 85 and older: community based study. BMJ 1998, 316:1780-1784.
12. Buxbaum J.D., Cullen E.I., Freidhoff L.T. Pharmacological concentrations of the HMG-COA reductase inhibitor lovastatin decrease the formation of the Alzheimer B-amyloid peptide in vitro and in patients. Front. Biosci. 2002, 7:50-59.
13. Buxbaum J.D., Geoghagen N.S., Friedhoff L.T. Cholesterol depletion with physiological concentrations of a statin decreases the formation of the Alzheimer amyloid Abeta peptide. J. Alzheimer's Dis. 2001, 3(2):221-229.
14. Carloni S., Girelli S., Buonocore G., Longini M., Balduini W. Simvastatin acutely reduces ischemic brain damage in the immature rat via Akt and CREB activation. Exp. Neurol. 2009, 220(1):82-89.
15. Carlsson C.M., Nondahl D.M., Klein B.E., McBride P.E., Sager M.A., Schubert C.R., Klein R., Cruickshanks K.J. Increased atherogenic lipoproteins are associated with cognitive impairment: effects of statins and subclinical atherosclerosis. Alzheimer Dis. Assoc. Disord. 2009, 23(1):11-17.
16. Carod-Artal F.J. Statins and cerebral vasomotor reactivity: implications for a new therapy?. Stroke 2006, 37(10):2446-2448.
17. Corzo L., Zas R., Rodríguez S., Fernández-Novoa L., Cacabelos R. Decreased levels of serum nitric oxide in different forms of dementia. Neurosci. Lett. 2007, 420(3):263-267.
18. Cui X., Chopp M., Zacharek A., Roberts C., Lu M., Savant-Bhonsale S., Chen J. Chemokine, vascular and therapeutic effects of combination simvastatin and BMSC treatment of stroke. Neurobiol. Dis. 2009, 36(1):35-41.
19. Di Napoli P., Taccardi A.A., Oliver M., De Caterina R. Statins and stroke: evidence for cholesterol-independent effects. Eur. Heart J. 2002, 23(24):1908-1921.
20. Endo A., Kuroda M., Tsujita Y. ML-236A, ML-236B, ML-236C, new inhibitors of cholesterogenesis produced by Pennicillium citrinum. J. Antibiot. 1976, 29:1346-1348.
21. Endres M., Laufs U., Huang Z., Nakamura T., Huang P., Moskowitz M.A., Liao J.K. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. U. S. A. 1998, 95(15):8880-8885.
22. Endres M., Laufs U., Liao J.K., Moskowitz M.A. Targeting eNOS for stroke protection. Trends Neurosci. 2004, 27:283-289.
23. Erdös B., Snipes J.A., Tulbert C.D., Katakam P., Miller A.W., Busija D.W. Rosuvastatin improves cerebrovascular function in Zucker obese rats by inhibiting NAD(P)H oxidase-dependent superoxide production. Am. J. Physiol, Heart Circ. Physiol. 2006, 290(3):H1264-H1270.
24. Evans R.M., Emsley C.L., Gao S., Sahota A., Hall K.S., Farlow M.R., Hendrie H. Serum cholesterol, APOE genotype, and the risk of Alzheimer's disease: a population-based study of African Americans. Neurology 2000, 54:240-242.
25. Fernández A., Llacuna L., Fernández-Checa J.C., Colell A. Mitochondrial cholesterol loading exacerbates amyloid beta peptide-induced inflammation and neurotoxicity. J. Neurosci. 2009, 29(20):6394-6405.
26. Furberg C.D. Natural statins and stroke risk. Circulation 1999, 99:185-188.
27. Furman C., Copin C., Kandoussi M., Davidson R., Moreau M., McTaggiart F., Chapman M.J., Fruchart J.C., Rouis M. Rosuvastatin reduces MMP-7 secretion by human monocyte-derived macrophages: potential relevance to atherosclerotic plaque stability. Atherosclerosis 2004, 174(1):93-98.
28. Ghosh A., Roy A., Matras J., Brahmachari S., Gendelman H.E., Pahan K. Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease. J. Neurosci. 2009, 29(43):13543-13556.
29. Gianella A., Nobili E., Abbate M., Zoja C., Gelosa P., Mussoni L., Bellosta S., Canavesi M., Rottoli D., Guerrini U., Brioschi M., Banfi C., Tremoli E., Remuzzi G., Sironi L. Rosuvastatin treatment prevents progressive kidney inflammation and fibrosis in stroke-prone rats. Am. J. Pathol. 2007, 170(4):1165-1177.
30. Gidday J.M., Gasche Y.G., Copin J.C., Shah A.R., Perez R.S., Shapiro S.D., Chan P.H., Park T.S. Leukocyte-derived matrix metalloproteinase-9 mediates blood-brain barrier breakdown and is proinflammatory after transient focal cerebral ischemia. Am. J. Physiol, Heart Circ. Physiol. 2005, 289:H558-H568.
31. Glorioso N., Troffa C., Filigheddu F., Dettori F., Soro A., Parpaglia P.P., Collatina S., Pahor M. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999, 34:1281-1286.
32. Gomez-Isla T., West H.L., Rebeck G.W., Harr S.D., Growdon J.H., Locascio J.J., Perls T.T., Lipsitz L.A., Hyman B.T. Clinical and pathological correlates of apolipoprotein E 4 in Alzheimer's disease. Ann. Neurol. 1996, 39:62-70.
33. Groemping Y., Rittinger K. Activation and assembly of the NADPH oxidase: a structural perspective. Biochem. J. 2005, 386:401-416.
34. Grundy S.M. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N. Engl. J. Med. 1988, 319:24-33.
35. Guasti L., Marino F., Cosentino M., Maio R.C., Rasini E., Ferrari M., Castiglioni L., Klersy C., Gaudio G., Grandi A.M., Lecchini S., Venco A. Prolonged statin-associated reduction in neutrophil reactive oxygen species and angiotensin II type 1 receptor expression: 1-year follow-up. Eur. Heart J. 2008, 29(9):1118-1126.
36. Gunstad J., Spitznagel M.B., Glickman E., Alexander T., Juvancic-Heltzel J., Walter K., Murray L. beta-Amyloid is associated with reduced cognitive function in healthy older adults. J. Neuropsychiatry, Clin. Neurosci. 2008, 20(3):327-330.
37. Haan M.N., Shemanski L., Jagust W.J., Manolio T.A., Kuller L. The role of APOE epsilon4 in modulating effects of other risk factors for cognitive decline in elderly persons. JAMA 1999, 282(1):40-46.
38. Handattu S.P., Garber D.W., Monroe C.E., van Groen T., Kadish I., Nayyar G., Cao D., Palgunachari M.N., Li L., Anantharamaiah G.M. Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer's disease. Neurobiol. Dis. 2009, 34(3):525-534.
39. Heeba G., Moselhy M., Hassan M., Khalifa M., Gryglewski R., Malinski T. Anti-atherogenic effect of statins: role of nitric oxide, peroxynitrite and haem oxygenase-1. Br. J. Pharmacol. 2009, 156(8):1256-1266.
40. Hernández-Romero M.C., Argüelles S., Villarán R.F., de Pablos R.M., Delgado-Cortés M.J., Santiago M., Herrera A.J., Cano J., Machado A. Simvastatin prevents the inflammatory process and the dopaminergic degeneration induced by the intranigral injection of lipopolysaccharide. J. Neurochem. 2008, 105(2):445-459.
41. Hildebrandt H., Haldenwanger A., Eling P. False recognition correlates with amyloid-beta (1-42) but not with total tau in cerebrospinal fluid of patients with dementia and mild cognitive impairment. J. Alzheimer's Dis. 2009, 16(1):157-165.
42. Hirsch, E. C., Hunot, S., Damier, P., Faucheux, B, 1998. Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration? Ann Neurol 44(3Suppl 1), S115-120. Review.
43. Hofman A., Ott A., Breteler M.M., Bots M.L., Slooter A.J., van Harskamp F., van Duijn C.N., Van Broeckhoven C., Grobbee D.E. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 1997, 349:151-154.
44. Höglund K., Syversen S., Lewczuk P., Wallin A., Wiltfang J., Blennow K. Statin treatment and a disease-specific pattern of beta-amyloid peptides in Alzheimer's disease. Exp. Brain Res. 2005, 164:205-214.
45. Hong H., Zeng J.S., Kreulen D.L., Kaufman D.I., Chen A.F. Atorvastatin protects against cerebral infarction via inhibition of NADPH oxidase-derived superoxide in ischemic stroke. Am. J. Physiol, Heart Circ. Physiol. 2006, 291(5):H2210-H2215.
46. Hu G., Antikainen R., Jousilahti P., Kivipelto M., Tuomilehto J. Total cholesterol and the risk of Parkinson disease. Neurology 2008, 70(21):1972-1979.
47. Huang X., Chen H., Miller W.C., Mailman R.B., Woodard J.L., Chen P.C., Xiang D., Murrow R.W., Wang Y.Z., Poole C. Lower low-density lipoprotein cholesterol levels are associated with Parkinson's disease. Mov. Disord. 2007, 22:377-381.
48. Ifergan I., Wosik K., Cayrol R., Kébir H., Auger C., Bernard M., Bouthillier A., Moumdjian R., Duquette P., Prat A. Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: relevance to multiple sclerosis. Ann. Neurol. 2006, 60(1):45-55.
49. Jick H., Zornberg G.L., Jick S.S., Seshadri S., Drachman D.A. Statins and the risk of dementia. Lancet 2000, 356(9242):1627-1631.
50. Kannel W.B., D'Agostino R.B., Silbershatz H. Blood pressure and cardiovascular morbidity and mortality rates in the elderly. Am. Heart J. 1997, 134:758-763.
51. Kario K., Motai K., Mitsuhashi T., Suzuki T., Nakagawa Y., Ikeda U., Matsuo T., Nakayama T., Shimada K. Autonomic nervous system dysfunction in elderly hypertensive patients with abnormal diurnal blood pressure variation: relation to silent cerebrovascular disease. Hypertension 1997, 30:1504-1510.
52. Kelly M.A., Shuaib A., Todd K.G. Matrix metalloproteinase activation and blood-brain barrier breakdown following thrombolysis. Exp. Neurol. 2006, 200:38-49.
53. Koladiya R.U., Jaggi A.S., Singh N., Sharma B.K. Ameliorative role of atorvastatin and pitavastatin in l-methionine induced vascular dementia in rats. BMC Pharmacol. 2008, 8:14.
54. Koob A.O., Ubhi K., Paulsson J.F., Kelly J., Rockenstein E., Mante M., Adame A., Masliah E. Lovastatin ameliorates alpha-synuclein accumulation and oxidation in transgenic mouse models of alpha-synucleinopathies. Exp. Neurol. 2010, 221(2):267-274.
55. Kunte H., Amberger N., Busch M.A., Rückert R.I., Meiners S., Harms L. Markers of instability in high-risk carotid plaques are reduced by statins. J. Vasc. Surg. 2008, 47(3):513-522.
56. Kureishi Y., Luo Z., Shiojima I., Bialik A., Fulton D., Lefer D.J., Sessa W.C., Walsh K. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat. Med. 2000, 6(9):1004-1010.
57. Laufs U., La Fata V., Liao J. Inhibition of 3.hydroxy-3methylglutaryl (HMG)-CoA reductase blocks hypoxia mediated down-regulation of endothelial nitric oxide synthase. J. Biol. Chem. 1997, 50:31725-31739.
58. Laufs U., La Fata V., Plutzky J., Liao J.K. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998, 97:1129-1135.
59. Laufs U., Liao J.K. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J. Biol. Chem. 1998, 273:24266-24271.
60. Laufs U., Liao J.K. Targeting Rho in cardiovascular disease. Circ. Res. 2000, 87:526-528.
61. Li G., Larson E.B., Sonnen J.A., Shofer J.B., Petrie E.C., Schantz A., Peskind E.R., Raskind M.A., Breitner J.C., Montine T.J. Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology 2007, 69(9):878-885.
62. Lieberman A., Lyons K., Levine J., Myerburg R. Statins, cholesterol, co-enzyme Q10, and Parkinson's disease. Parkinsonism Relat. Disord. 2005, 11(2):81-84.
63. Liu J., Garcia-Gardena G., Sessa W.C. Palmitoylation of nitric oxide synthase is necessary for optimal stimulated release of nitric oxide: implications for caveolae localization. Biochemistry 1996, 35:13277-13281.
64. Liu X.S., Zhang Z.G., Zhang L., Morris D.C., Kapke A., Lu M., Chopp M. Atorvastatin downregulates tissue plasminogen activator-aggravated genes mediating coagulation and vascular permeability in single cerebral endothelial cells captured by laser microdissection. J. Cereb. Blood Flow Metab. 2006, 26(6):787-796.
65. Maack C., Kartes T., Kilter H., Schäfers H.J., Nickenig G., Böhm M., Laufs U. Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment. Circulation 2003, 108(13):1567-1574.
66. Mann D.M., Iwatsubo T., Pickering-Brown S.M., Owen F., Saido T.C., Perry R.H. Preferential deposition of amyloid beta protein [A] in the form A 40 in Alzheimer's disease is associated with a gene dosage effect of the apolipoprotein E 4 allele. Neurosci. Lett. 1997, 221:81-84.
67. Mayanagi K., Katakam P.V., Gáspár T., Domoki F., Busija D.W. Acute treatment with rosuvastatin protects insulin resistant (C57BL/6J ob/ob) mice against transient cerebral ischemia. J. Cereb. Blood Flow Metab. 2008, 28(12):1927-1935.
68. Mogi M., Kondo T., Mizuno Y., Nagatsu T. p53 protein, interferongamma, and NF-kappaB levels are elevated in the parkinsonian brain. Neurosci. Lett. 2007, 414(1):94-97.
69. Moro M.A., Cardenas A., Hurtado O., Leza J.C., Lizasoain I. Role of nitric oxide after brain ischaemia. Cell Calcium 2004, 36:265-275.
70. Mutez E., Duhamel A., Defebvre L., Bordet R., Destée A., Kreisler A. Lipid-lowering drugs are associated with delayed onset and slower course of Parkinson's disease. Pharmacol. Res. 2009, 60(1):41-45.
71. Nakamura H., Arakawa K., Itakura H., Kitabatake A., Goto Y., Toyota T., Nakaya N., Nishimoto S., Muranaka M., Yamamoto A., Mizuno K., Ohashi Y. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006, 368:1155-1163. MEGA Study Group.
72. Newman A.B., Fitzpatrick A.L., Lopez O., Jackson S., Lyketsos C., Jagust W., Ives D., Dekosky S.T., Kuller L.H. Dementia and Alzheimer's disease incidence in relationship to cardiovascular disease in the Cardiovascular Health Study cohort. J. Am. Geriatr. Soc. 2005, 53:1101-1107.
73. Nicholson A.M., Ferreira A. Increased membrane cholesterol might render mature hippocampal neurons more susceptible to beta-amyloid-induced calpain activation and tau toxicity. J. Neurosci. 2009, 29(14):4640-4651.
74. Ostrowski S.M., Wilkinson B.L., Golde T.E., Landreth G. Statins reduce amyloid-beta production through inhibition of protein isoprenylation. J. Biol. Chem. 2007, 282(37):26832-26844.
75. Otto A., Fontaine J., Tschirhart E., Fontaine D., Berkenboom G. Rosuvastatin treatment protects against nitrate-induced oxidative stress in eNOS knockout mice: implication of the NAD(P)H oxidase pathway. Br. J. Pharmacol. 2006, 148(4):544-552.
76. Ovbiagele B., Saver J.L., Starkman S., Kim D., Ali L.K., Jahan R., Duckwiler G.R., Viñuela F., Pineda S., Liebeskind D.S. Statin enhancement of collateralization in acute stroke. Neurology 2007, 68(24):2129-2131.
77. Packard C.J., Westendorp R.G., Stott D.J., Caslake M.J., Murray H.M., Shepherd J., Blauw G.J., Murphy M.B., Bollen E.L., Buckley B.M., Cobbe S.M., Ford I., Gaw A., Hyland M., Jukema J.W., Kamper A.M., Macfarlane P.W., Jolles J., Perry I.J., Sweeney B.J., Twomey C. Association between apolipoprotein E4 and cognitive decline in elderly adults. J. Am. Geriatr. Soc. 2007, 55(11):1777-1785. Prospective Study of Pravastatin in the Elderly at Risk Group.
78. Panza F., D'Introno A., Colacicco A.M., Capurso C., Pichichero G., Capurso S.A., Capurso A., Solfrizzi V. Lipid metabolism in cognitive decline and dementia. Brain Res. Rev. 2006, 51(2):275-292.
79. Panza F., Solfrizzi V., Colacicco A.M., D'Introno A., Capurso C., Palasciano R., Todarello O., Capurso S., Pellicani V., Capurso A. Cerebrovascular disease in the elderly: lipoprotein metabolism and cognitive decline. Aging Clin. Exp. Res. 2006, 18(2):144-148.
80. Papassotiropoulos A., Streffer J.R., Tsolaki M., Schmid S., Thal D., Nicosia F., Iakovidou V., Maddalena A., Lütjohann D., Ghebremedhin E., Hegi T., Pasch T., Träxler M., Brühl A., Benussi L., Binetti G., Braak H., Nitsch R.M., Hock C. Increased brain beta-amyloid load, phosphorylated tau, and risk of Alzheimer disease associated with an intronic CYP46 polymorphism. Arch. Neurol. 2003, 60(1):29-35.
81. Paterniti S., Verdier-Taillefer M.H., Geneste C., Bisserbe J.C., Alperovitch A. Low blood pressure and risk of depression in the elderly: a prospective community based study. Br. J. Psychiatry 2000, 176:464-467.
82. Prinz V., Laufs U., Gertz K., Kronenberg G., Balkaya M., Leithner C., Lindauer U., Endres M. Intravenous rosuvastatin for acute stroke treatment: an animal study. Stroke 2008, 39(2):433-438.
83. Reitz C., Tang M.X., Luchsinger J., Mayeux R. Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch. Neurol. 2004, 61:705-714.
84. Rikitake Y., Liao J.K. Rho GTPases, statins, and nitric oxide. Circ. Res. 2005, 97:1232-1235.
85. Rockwood K., Kirkland S., Hogan D.B., MacKnight C., Merry H., Verreault R., Wolfson C., McDowell I. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch. Neurol. 2002, 59(2):223-227.
86. Rosenberg G.A. Matrix metalloproteinases in neuroinflammation. Glia 2002, 39:279-291.
87. Rosenberg G.A., Cunningham L.A., Wallace J., Alexander S., Estrada E.Y., Grossetete M., Razhagi A., Miller K., Gearing A. Immunohistochemistry of matrix metalloproteinases in reperfusion injury to rat brain: activation of MMP-9 linked to stromelysin-1 and microglia in cell cultures. Brain Res. 2001, 893:104-112.
88. Samii A., Carleton B.C., Etminan M. Statin use and the risk of Parkinson disease: a nested case control study. J. Clin. Neurosci. 2008, 15(11):1272-1273.
89. Schuster S., Nadjar A., Guo J.T., Li Q., Ittrich C., Hengerer B., Bezard E. The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor lovastatin reduces severity of L-DOPA-induced abnormal involuntary movements in experimental Parkinson's disease. J. Neurosci. 2008, 28(17):4311-4316.
90. Selley M.L. Simvastatin prevents 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced striatal dopamine depletion and protein tyrosine nitration in mice. Brain Res. 2005, 1037(1-2):1-6.
91. Shaw G., Karmen R. A conserved AU sequence from the 3' untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell 1986, 46:659-667.
92. Simons M., Keller P., Dichgans J., Schulz J.B. Cholesterol and Alzheimer's disease: is there a link?. Neurology 2001, 57(6):1089-1093.
93. Sparks D.L., Connor D.J., Sabbagh M.N., Petersen R.B., Lopez J., Browne P. Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial. Acta Neurol. Scand. Suppl. 2006, 185:3-7.
94. Sparks D.L., Kryscio R.J., Sabbagh M.N., Connor D.J., Sparks L.M., Liebsack C. Reduced risk of incident AD with elective statin use in a clinical trial cohort. Curr. Alzheimer Res. 2008, 5(4):416-421.
95. Sposito A.C., Mansur A.P., Coelho O.R., Nicolau J.C., Ramires J.A. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin converting enzyme inhibitors (enalapril or lisinopril). Am. J. Cardiol. 1999, 83:1497-1499.
96. Sterzer P., Meintzschel F., Rösler A., Lanfermann H., Steinmetz H., Sitzer M. Pravastatin improves cerebral vasomotor reactivity in patients with subcortical small-vessel disease. Stroke 2001, 32(12):2817-2820.
97. Stoll G., Jander S. The role of microglia and macrophages in the pathophysiology of the CNS. Prog. Neurobiol. 1999, 58(3):233-247. Review.
98. Suribhatla S., Dennis M.S., Potter J.F. A study of statin use in the prevention of cognitive impairment of vascular origin in the UK. J Neurol Sci. 2005, 229-230:47-50.
99. Turner N.A., O'Regan D.J., Ball S.G., Porter K.E. Simvastatin inhibits MMP-9 secretion from human saphenous vein smooth muscle cells by inhibiting the RhoA/ROCK pathway and reducing MMP-9 mRNA levels. FASEB J. 2005, 19(7):804-806.
100. Vaughan C.J., Delanty N., Basson C.T. Do statins afford neuroprotection in patients with cerebral ischaemia and stroke?. CNS Drugs 2001, 15(8):589-596.
101. Wahner A.D., Bronstein J.M., Bordelon Y.M., Ritz B. Statin use and the risk of Parkinson disease. Neurology 2008, 70(16 Pt 2):1418-1422.
102. Wang H., Lynch J.R., Song P., Yang H.J., Yates R.B., Mace B., Warner D.S., Guyton J.R., Laskowitz D.T. Simvastatin and atorvastatin improve behavioral outcome, reduce hippocampal degeneration, and improve cerebral blood flow after experimental traumatic brain injury. Exp. Neurol. 2007, 206(1):59-69.
103. Wang Q., Tang X.N., Yenari M.A. The inflammatory response in stroke. J. Neuroimmunol. 2007, 184(1-2):53-68.
104. Wang Q., Ting W.L., Yang H., Wong P.T. High doses of simvastatin upregulate dopamine D1 and D2 receptor expression in the rat prefrontal cortex: possible involvement of endothelial nitric oxide synthase. Br. J. Pharmacol. 2005, 144(7):933-939.
105. Wang Q., Wang P.H., McLachlan C., Wong P.T. Simvastatin reverses the downregulation of dopamine D1 and D2 receptor expression in the prefrontal cortex of 6-hydroxydopamine-induced Parkinsonian rats. Brain Res. 2005, 1045(1-2):229-233.
106. Wang Q., Zengin A., Deng C., Li Y., Newell K.A., Yang G.Y., Lu Y., Wilder-Smith E.P., Zhao H., Huang X.F. High dose of simvastatin induces hyperlocomotive and anxiolytic-like activities: the association with the up-regulation of NMDA receptor binding in the rat brain. Exp. Neurol. 2009, 216(1):132-138.
107. Wang S., Lee S.R., Guo S.Z., Kim W.J., Montaner J., Wang X., Lo E.H. Reduction of tissue plasminogen activator-induced matrix metalloproteinase-9 by simvastatin in astrocytes. Stroke 2006, 37(7):1910-1912.
108. Wassmann S., Laufs U., Bäumer A.T., Müller K., Konkol C., Sauer H., Böhm M., Nickenig G. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol. Pharmacol. 2001, 59(3):646-654.
109. Watanabe N., Imai Y., Nagai K., Tsuji I., Satoh H., Sakuma M., Sakuma H., Kato J., Onodera-Kikuchi N., Yamada M., Abe F., Hisamichi S., Abe K. Nocturnal blood pressure and silent cerebrovascular lesions in elderly Japanese. Stroke 1996, 27(8):1319-1327.
110. Whitehouse P.J., Sciulli C.G., Mason R.M. Dementia drug development: use of information systems to harmonize global drug development. Psychopharmacol. Bull. 1997, 33(1):129-133.
111. Wolozin B., Kellman W., Ruosseau P., Celesia G.G., Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 2000, 57(10):1439-1443.
112. Wolozin B., Wang S.W., Li N.C., Lee A., Lee T.A., Kazis L.E. Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med. 2007, 5:20.
113. Yaffe K., Barrett-Connor E., Lin F., Grady D. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch. Neurol. 2002, 59:378-384.
114. Yamada M., Huang Z., Dalkara T., Endres M., Laufs U., Waeber C., Huang P.L., Liao J.K., Moskowitz M.A. Endothelial nitric oxide synthase-dependent cerebral blood flow augmentation by L-arginine after chronic statin treatment. J. Cereb. Blood Flow Metab. 2000, 20(4):709-717.
115. Yamanouchi D., Banno H., Nakayama M., Sugimoto M., Fujita H., Kobayashi M., Kuwano H., Komori K. Hydrophilic statin suppresses vein graft intimal hyperplasia via endothelial cell-tropic Rho-kinase inhibition. J. Vasc. Surg. 2005, 42(4):757-764.
116. Zhou Q., Liao J.K. Rho kinase: an important mediator of atherosclerosis and vascular disease. Curr. Pharm. Des. 2009, 15(27):3108-3115.